The committee noted that the clinical evidence showed Optilume to be effective in improving clinically relevant outcomes including anatomical success, peak flow rate and international prostate symptom ...
PORTSMOUTH, N.H., Jan. 17, 2025 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leader in diagnostic and therapeutic medical technologies, has reached a significant milestone with its ...
PORTSMOUTH, N.H., July 10, 2025 /PRNewswire/ -- Effective July 1, 2025, Blue Cross Blue Shield of Michigan (BCBSM) has issued a new medical policy under CPT code 52284, extending coverage for Laborie ...
The Optilume device includes a balloon coated with paclitaxel. The Food and Drug Administration (FDA) has approved the Optilume ® Urethral Drug Coated Balloon (DCB) to treat patients with obstructive ...
PORTSMOUTH, N.H., April 30, 2024 /PRNewswire/ -- Laborie Medical Technologies Corp. (Laborie), a leading diagnostic and therapeutic medical technology company, welcomed the inclusion of Optilume ® ...
LAS VEGAS -- A novel, non-ablative intervention for lower urinary tract symptoms (LUTS) produced rapid, durable symptom relief with no adverse effect on sexual function, long-term results from ...
Urotronic's Drug Coated Balloon Provides Minimally-Invasive, Durable Alternative for Stricture Patients in Europe MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Urotronic, Inc., a Minnesota-based medical ...
PORTSMOUTH, N.H., Oct. 28, 2024 /PRNewswire/ -- Leading diagnostic and therapeutic medical technology company, Laborie Medical Technologies Corp (Laborie), announced today that the American Medical ...
The US Food and Drug Administration has approved a new catheter designed to treat urinary tract symptoms of an enlarged prostate, also known as benign prostate hyperplasia (BPH). Designed and marketed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results